Perimenopausal weight gain, especially the shift toward belly fat, is one of the most frustrating and least controllable symptoms of this transition. In the last few years, GLP-1 receptor agonist medications, originally developed for diabetes and now widely prescribed for weight management, have become part of that conversation, including in Indian clinics.

This is not a recommendation to start one. It’s an explanation of what these medications actually do, how they relate to perimenopausal weight gain specifically, and what’s worth understanding before that conversation with your gynaecologist or physician.

Why Perimenopausal Weight Gain Is Different

Before getting to medication, it’s worth understanding why this particular weight gain resists the usual advice. As oestrogen declines, fat storage shifts from hips and thighs toward the abdomen. Declining oestrogen also reduces insulin sensitivity and increases cortisol reactivity, both of which favour fat storage around the midsection specifically. Add in the muscle loss that accompanies hormonal ageing, which lowers your resting metabolic rate, and it becomes clear why eating and moving exactly as you did in your 30s can still result in weight gain in your 40s.

This is metabolic, not a matter of willpower, which is exactly why some women and their doctors are now looking at medication as one tool among several.

What GLP-1 Medications Actually Do

How This Class of Medication Works
Slows digestionFood leaves the stomach more slowly, extending the feeling of fullness after meals
Reduces appetite signalsActs on appetite centres in the brain, reducing hunger and food noise between meals
Improves insulin responseHelps the body use insulin more effectively, relevant given perimenopause's own effect on insulin sensitivity
Was developed for diabetesOriginally used to manage blood sugar in type 2 diabetes, later found to produce significant weight loss as a secondary effect

These medications are given as a weekly injection, and are prescribed under two broad generic drug classes: semaglutide-based and tirzepatide-based formulations. Both require a prescription and ongoing medical supervision in India; they are not available over the counter.

Does It Address the Hormonal Cause, or Just the Weight?

This is the important distinction. GLP-1 medications reduce appetite and improve insulin sensitivity, which can produce real weight loss, including a reduction in visceral (abdominal) fat. What they do not do is restore declining oestrogen or address the muscle loss, sleep disruption, or other perimenopausal symptoms happening at the same time.

For some women, this means GLP-1 medication and hormone replacement therapy (HRT) are discussed together, since HRT addresses the hormonal drivers directly while a GLP-1 medication addresses appetite and insulin resistance. For others, lifestyle measures, particularly strength training to preserve muscle mass, remain the more appropriate first step before adding medication at all. This is a decision to make with a doctor who understands both your metabolic picture and your hormonal one, not in isolation.

In the Indian context: Access to these medications in India has expanded significantly, but so has informal, unsupervised use, sometimes obtained without a proper medical evaluation. Given the muscle loss, nutrient needs, and hormonal complexity already at play in perimenopause, starting one of these medications without medical supervision carries real risk, including excessive muscle loss on top of what perimenopause is already causing.

What to Ask Before Starting

  • Is this appropriate given my current hormonal stage, and would HRT address some of this more directly?
  • How will we protect my muscle mass while I’m on this medication, since GLP-1-related weight loss can include significant muscle loss without deliberate protein intake and strength training?
  • What are the common side effects, and how are they monitored?
  • Is this intended as a short-term or long-term treatment, and what happens to weight and appetite if I stop?
  • Does my current health profile (thyroid, gallbladder, pancreatic history) affect suitability?

Who Should Be Cautious

These medications are not appropriate for everyone. Women with a personal or family history of certain thyroid cancers, active gallbladder disease, or a history of pancreatitis need a careful individual risk discussion with their doctor. They are also not typically recommended during active attempts to conceive.

If you’re trying to understand whether your weight changes are primarily hormonal, primarily metabolic, or a mix, take our free symptom check to get a clearer picture of your overall pattern before that conversation with your doctor.

Frequently Asked Questions

Will I regain the weight if I stop taking it? For many people, appetite and weight tend to return toward baseline after stopping, since the medication doesn’t change the underlying metabolic drivers on its own. This is why it’s usually discussed as part of a longer-term plan involving diet, strength training, and, where relevant, hormone therapy, rather than a standalone fix.

Can I take this alongside HRT? Many women do use both under medical supervision, since they act through different mechanisms; one addresses appetite and insulin sensitivity, the other addresses hormonal decline directly. This combination should be planned and monitored by your doctor, not self-directed.

Is this only for women who are significantly overweight? No. Prescribing criteria vary, and some doctors will discuss it for perimenopausal women with more moderate weight gain, particularly abdominal fat linked to metabolic changes, though this varies by individual clinical picture and doctor.